Preliminary Clinical Study On The Morbidity Of Metabolic Syndrome In Breast Cancer Patients

Background and purpose:Breast cancer is the most common malignant tumor in females. Although the morbidity of breast cancer in China is lower than that of western countries, it’s rising year by year. Metabolic syndrome, another diseases affecting various people, has a high incidence. Recent years there were researches suggesting some relation between metabolic syndrome and breast cancer, without unified conclusion, though. Besides, breast cancer, as a hormone-dependent malignant tumor, might have different relation with metabolic syndrome depending different menstrual status. This study investigated into the morbidity of metabolic syndrome in breast cancer patients and impact of metabolic syndrome on the occurrence of breast cancer. Furthermore, we discuss the relation between metabolic syndrome and breast cancer stratified by menstrual status.Method:From October, 2015 to February, 2016, 208 patients initially diagnosed with breast cancer in the First Affiliated Hospital of Chongqing Medical University(Chongqing Breast Cancer Center) were included as study objects. At the same time, 71 patients initially diagnosed with benign breast disease were put on control group. We obtained age, sex, pathological diagnosis, menstrual status, condition of hypertension, condition of diabetes, and condition of hyperlipidemia from medical record system; we perform artificial measurement of waist circumference and blood pressure; fasting venous blood samples were drawn to assess serum lipid profile and serum glucose. Morbidity of metabolic syndrome in breast cancer group and control group, relation between metabolic syndrome and breast cancer were analyzed. Furthermore, we carried out analysis of relation between metabolic syndrome and breast cancer according to different menstrual status.Rusult:1. The average age of breast cancer patients was 50.20(ranging from 35 to 75), while the average age of control group was 48.06(ranging from 35 to 75). No difference was observed between two groups in terms of age(P>0.05). There were 119 premenopausal breast cancer patients(age: 43.93±4.27) and 89 postmenopausal breast cancer patients(age: 58.58±6.94). As for benign breast disease group, there were 50 cases on premenopausal group(age: 43.94±3.78) and 21 cases on postmenopausal group(age: 57.86±8.75). No difference was observed between trial group and control group in pre- and postmenopausal status(P>0.05).2. The morbidity of metabolic syndrome in breast cancer group was 27.40%(57/208), while the morbidity of metabolic syndrome in control group was 23.94%(17/71), there were no significant difference between them(p=0.569). It was the same with separate indicator of metabolic syndrome(central obesity, increased blood pressure, low HDL-C, high TG and increased serum glucose)- no difference was detected between breast cancer and benign breast disease when it came to the relation with metabolic syndrome.3. In premenopausal famales, the incidence of metabolic syndrome in breast cancer patients was 18.49%(22/119), and 22%(11/50)in control group. No static significance was detected(p=0.60). As for separate indicator of metabolic syndrome, central obesity rate was 37.82%(45/119)in premenopausal breast cancer group, and 54%(27/50)in control group. P value was borderline significant(p=0.0521). The rest of indicators(increased blood pressure, low HDL-C, high TG and increased serum glucose) displayed no relation with morbidity of breast cancer compared with control group(p>0.05).4. In postmenopausal females, the incidence of metabolic syndrome in breast cancer patients was 39.33%(35/89), and 21.35%(6/21)in control group. No static significance was detected(p=0.36). As for separate indicator of metabolic syndrome, increased triglyceride rate was 21.35%(19/89)in postmenopausal breast cancer group, and 0%(0/21)in control group(p=0.021), which suggested a negative relation between breast cancer and triglyceride in postmenopausal females. The rest of indicators(central obesity, increased blood pressure, low HDL-C, and increased serum glucose) displayed no relation with morbidity of breast cancer compared with control group(p>0.05).5. Except for decreased high density lipid protein cholesterol value and increased triglyceride in premenopausal females, incidence of metabolic syndrome and its separate indicators showed general discipline as: postmenopausal breast cancer group> postmenopausal control group> premenopausal control group> premenopausal breast cancer group.Conclusion:1. In this study, there was some relation between the incidence of metabolic syndrome and pre- or postmenopausal breast cancer, not significant, though. General trend was positive relation between metabolic syndrome and breast cancer in postmenopausal females and negative in premenopausal females.2. Increased triglyceride was a risk factor for breast cancer in postmenopausal females.3. Central obesity displayed negative relation with breast cancer in premenopausal females.4. More attention should be paid to screening of metabolic syndrome in breast cancer patients to detect the real relation between metabolic syndrome and breast cancer depending on different menstrual status, thus early intervention might be adopted to protect females from exposure to risk factors.